Absci is a promising company as their recent clinical data on ABS-201 has de-risked the drug, leading to a potential inflection point in 2026 for proof-of-concept efficacy. With a potential peak total revenue of $501M in 2036 and a convenient dosing paradigm, Absci's AI-powered drug creation platform has the potential for success. However, the company's ability to obtain regulatory approval for their drugs may impact their development timelines and decisions.
Bears say
Absci is a drug and target discovery company that utilizes AI and synthetic biology, but all of their programs are still in early stages; therefore, there is no guarantee of success in the clinic.
Absci Corp (ABSI) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Get the latest Absci Corp (ABSI) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.
According to 7 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $12.84, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $12.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.
Get the latest Absci Corp (ABSI) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.